Krajska zdravotni a.s.

Research site

Czechia Socialni Pece 3316/12a, Severni Terasa, 400 11 Usti Nad Labem, Czechia

7 trials recruiting
Colitis ulcerative · Hypertriglyceridaemia · Psoriasis
Adults and children

About Specializations

Krajska zdravotni a.s. in Usti Nad Labem, Czechia specialises in clinical trials of conditions such as Colitis ulcerative, Hypertriglyceridaemia, Psoriasis, Crohn's disease, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Socialni Pece 3316/12a, Severni Terasa400 11 Usti Nad LabemCzechia

Open in maps ↗

Recruiting now: 7 trials
Conditions studied: 24

More sites in Usti Nad Labem Czechia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

24 clinical trials

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Deucravacitinib
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Hypereosinophilic syndrome

Recruiting

A Study of Depemokimab and Prednisolone in Adults with Hypereosinophilic Syndrome (HES)

Registered drug

A Study of Depemokimab and Prednisolone in Adults with Hypereosinophilic Syndrome (HES)

Registered drug

Czechia

Participants:18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Atrial fibrillation

Recruiting

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational

Czechia

Participants:65+ years
Substances:Abelacimab
Sponsor:Anthos Therapeutics Inc.

Contact Research Centre

Short-bowel syndrome

Recruiting

Study of glepaglutide compared to placebo for patients with short bowel syndrome with intestinal failure

Investigational

Study of glepaglutide compared to placebo for patients with short bowel syndrome with intestinal failure

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Glepaglutide
Sponsor:Zealand Pharma A/S

Contact Research Centre

Colitis ulcerative+1

Recruiting

Study on Long-term Safety of Zasocitinib for Adults with Moderate to Severe Ulcerative Colitis and Crohn's Disease

InvestigationalNo placebo

Study on Long-term Safety of Zasocitinib for Adults with Moderate to Severe Ulcerative Colitis and Crohn's Disease

InvestigationalNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Zasocitinib
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn's Disease

Investigational

Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn's Disease

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:RO7790121
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Clostridium difficile colitis+1

Recruiting

Study on Optimizing Antibiotic Treatment for Clostridioides Difficile Infection with Vancomycin Hydrochloride in Adult Patients

Registered drug

Study on Optimizing Antibiotic Treatment for Clostridioides Difficile Infection with Vancomycin Hydrochloride in Adult Patients

Registered drug

Czechia

Participants:18–64 years · 65+ years
Substances:Vancomycin Hydrochloride
Sponsor:Fakultni Nemocnice Bulovka

Contact Research Centre

Hypertriglyceridaemia

Not recruiting

Long-Term Safety Study of Plozasiran for Adults with High Triglycerides

InvestigationalNo placebo

Long-Term Safety Study of Plozasiran for Adults with High Triglycerides

InvestigationalNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
Sponsor:Arrowhead Pharmaceuticals Inc.

Contact Research Centre

Hidradenitis

Not recruiting

Study on Long-term Effects of Secukinumab in Patients with Moderate to Severe Hidradenitis Suppurativa

Registered drug

Study on Long-term Effects of Secukinumab in Patients with Moderate to Severe Hidradenitis Suppurativa

Registered drug

Czechia

Participants:18–64 years · 65+ years
Substances:Secukinumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Hypertriglyceridaemia

Not recruiting

Study of Plozasiran for Adults with Severe Hypertriglyceridemia

Investigational

Study of Plozasiran for Adults with Severe Hypertriglyceridemia

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
Sponsor:Arrowhead Pharmaceuticals Inc.

Contact Research Centre

Hypertriglyceridaemia

Not recruiting

Study to Evaluate Plozasiran for Adults with High Triglycerides

Investigational

Study to Evaluate Plozasiran for Adults with High Triglycerides

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
Sponsor:Arrowhead Pharmaceuticals Inc.

Contact Research Centre

Psoriasis

Not recruiting

Study on Long-Term Safety and Efficacy of Deucravacitinib for Patients with Moderate-to-Severe Plaque Psoriasis

Investigational

Study on Long-Term Safety and Efficacy of Deucravacitinib for Patients with Moderate-to-Severe Plaque Psoriasis

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Deucravacitinib
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites